Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.
| Autor: | Kousari AE; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Wilson MP; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Hawkins KL; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Denver Health and Hospital Authority, Denver, CO, USA., Bandali MM; School of Medicine, University of Colorado, Aurora, CO, USA., Henao-Martínez AF; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Gardner EM; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.; Denver Health and Hospital Authority, Denver, CO, USA., Erlandson KM; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | HIV research & clinical practice [HIV Res Clin Pract] 2024 Dec; Vol. 25 (1), pp. 2339576. Date of Electronic Publication: 2024 Jun 03. |
| Abstrakt: | Background: Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively "weight-neutral" drug; however, there is little data describing its effect on weight change in routine clinical practice. Methods: We conducted a retrospective chart review of weight change among people with HIV changing from an INSTI- to a non-INSTI regimen with DOR. Results: At the time of ART switch, among 49 people with HIV, the mean age was 47 years, 24% were female, and 75% had HIV-1 viral load <200 copies/mL. Most (55%) people with HIV were taking bictegravir/TAF/emtricitabine prior to the switch. Although 84% switched due to concerns about weight gain, only 16% had a weight gain of ≥10% in the year preceding, and 49% had no substantial change in weight. 86% switched to DOR/lamivudine/tenofovir disoproxil fumarate. A weight decrease (-2.6% [95% CI: -5.1, -0.1%, p = .041] was seen over the year following the ART switch. Weight change prior to switch was greatest in the year 2021 compared to 2019, 2020, and 2022. Conclusions: Overall, modest changes in weight were seen following ART switch from INSTI-based regimen to a DOR-based, non-INSTI regimen. Further investigations with larger people with HIV cohorts will be helpful to guide clinical practice, while the impact of the COVID-19 pandemic on weight change should also be considered. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|